The most effective weight loss medications available today are injectable drugs that mimic gut hormones called GLP-1 and GIP. Tirzepatide (sold as Zepbound) and semaglutide (sold as Wegovy) consistently produce the largest weight loss in clinical trials, with tirzepatide leading the pack at roughly 20-25% of body weight over about 16 months. Which one is “best” for you depends on your insurance coverage, how you tolerate side effects, and whether you prefer injections or pills.
How These Medications Work
GLP-1 and GIP are hormones your gut naturally releases after eating. They signal your brain’s satiety center, particularly the hypothalamus, to dial down hunger. The newer weight loss drugs are synthetic versions of these hormones, designed to last much longer in the body than the natural versions do.
These drugs work on two fronts. In the brain, they activate neurons that increase feelings of fullness and reduce the reward response to food, making it easier to eat less without constantly fighting cravings. In the stomach, they slow the rate at which food empties into the intestines, which means you feel satisfied longer after a meal and experience smaller spikes in blood sugar and fat after eating. Tirzepatide activates both GLP-1 and GIP receptors simultaneously, which appears to be why it produces greater weight loss than semaglutide alone.
The Top Medications Compared
Tirzepatide (Zepbound)
Tirzepatide is a dual GLP-1/GIP receptor agonist and currently produces the highest average weight loss of any approved medication. In clinical trials, participants lost roughly 20-25% of their starting body weight over 72 weeks. It’s given as a weekly injection, starting at a low dose that gradually increases. Zepbound’s list price without insurance ranges from $499 to $1,049 per month depending on the dose, though Eli Lilly offers a savings card that can bring the cost to $25 per month for people with qualifying commercial insurance.
Semaglutide (Wegovy)
Semaglutide targets only the GLP-1 receptor. The injectable version (Wegovy) produces average weight loss of about 15-17% of body weight over 68 weeks. It’s also a once-weekly injection with a gradual dose increase. Semaglutide has additional clinical data showing cardiovascular benefits, including reduced risk of heart attacks and strokes in people with obesity and existing heart disease, which gives it an edge for that specific population.
High-Dose Oral Semaglutide
For people who strongly prefer a pill over an injection, a high-dose oral form of semaglutide (50 mg daily) showed a 15.1% average weight loss at 68 weeks in a phase 3 trial. That’s close to what the injectable version achieves. About 85% of participants on the oral version lost at least 5% of their body weight, and 54% lost at least 15%. The oral form requires taking the pill on an empty stomach with a small amount of water, then waiting at least 30 minutes before eating or drinking anything else.
Phentermine-Topiramate (Qsymia)
This older combination pill works through different pathways: one ingredient suppresses appetite while the other reduces food cravings. At the highest dose, it produces about 10% body weight loss. That’s roughly half what tirzepatide achieves, but Qsymia is available as a daily pill, has been on the market since 2012, and is generally less expensive. It’s not recommended for people with recent or unstable heart or blood vessel disease.
Who Qualifies for These Medications
The FDA approves weight loss medications for adults with a BMI of 30 or higher, or a BMI of 27 or higher when combined with a weight-related health condition like type 2 diabetes, high blood pressure, or high cholesterol. Adolescents aged 12-17 qualify if their BMI is at or above the 95th percentile for their age and sex.
Insurance coverage is a separate and often frustrating question. Many insurers still classify obesity medications as “lifestyle” drugs and exclude them from coverage. Medicare currently does not cover most weight loss medications, though this has been an active area of policy change. If your insurance does cover these drugs, you’ll typically need documentation of your BMI and at least one qualifying health condition, along with evidence that diet and exercise alone haven’t been sufficient.
Side Effects to Expect
Nausea is the most common side effect across all GLP-1-based medications, and it’s the reason doses start low and increase gradually. Most people find that nausea fades after the first few weeks at each dose level. Vomiting, diarrhea, and constipation are also common, particularly during dose escalation.
More serious but rarer complications deserve attention. Compared to people taking other weight loss drugs, GLP-1 users have a significantly higher rate of pancreatitis (about 9 times higher), bowel obstruction (about 4 times higher), and gastroparesis, a condition where the stomach empties abnormally slowly (about 3.7 times higher). These are still uncommon in absolute terms, but they mean you should take persistent, severe abdominal pain seriously and report it promptly. Biliary disease, including gallstones, also appears to be somewhat more common, though the data is less definitive.
What Happens When You Stop
This is the part most people don’t hear about upfront. A systematic review published in The Lancet found that people regain about 60% of their lost weight within one year of stopping GLP-1 medications. The regain doesn’t stop there: it plateaus at roughly 75% of the lost weight regained over the longer term. So if you lost 50 pounds on medication, you can expect to regain about 30 pounds within a year of stopping, and potentially closer to 37 pounds eventually.
This pattern reflects the fact that obesity involves persistent changes in the hormones that regulate hunger and metabolism. The medications correct those signals while you take them, but the underlying biology reasserts itself when you stop. For this reason, most clinicians now view these drugs as long-term or indefinite treatments, similar to blood pressure medication, rather than short courses you take and then discontinue.
What’s Coming Next
Retatrutide, a triple-action drug that activates GLP-1, GIP, and a third hormone receptor (glucagon), is in late-stage trials and showing remarkable results. In a phase 3 trial, participants on the 12 mg dose lost an average of 28.7% of their body weight (about 71 pounds) over 68 weeks. Nearly 40% of participants lost 30% or more of their starting weight. If approved, retatrutide would represent a meaningful jump beyond what tirzepatide already achieves.
Choosing the Right Option
If pure efficacy is your priority and cost isn’t a barrier, tirzepatide currently offers the best results among approved options. If you have existing cardiovascular disease, semaglutide has the strongest evidence for heart-related benefits. If you need a pill rather than an injection, high-dose oral semaglutide or phentermine-topiramate are reasonable choices, with oral semaglutide being the more effective of the two.
Cost often ends up being the deciding factor. Without insurance, you’re looking at $500 to $1,000 per month for the newer injectables, and that’s likely a lifelong expense given the weight regain data. Older options like phentermine-topiramate are more affordable but produce smaller results. The “best” medication is ultimately the one that produces meaningful weight loss, causes tolerable side effects, and fits within a treatment plan you can sustain for years.